Bone Health Technologies (BHT) is redefining the landscape of treatments available for low bone mass in postmenopausal women. At the prestigious Endo 2023, BHT showcased the groundbreaking Osteoboost. Selected as a “late-breaking abstract,” the presented data asserts the efficacy of Osteoboost in reducing the decline of bone strength and density.
The double-blinded, sham-controlled study included 126 postmenopausal women with low bone mass, who were not taking bone-active medications. Through Biomechanical Computed Tomography, the study observed that the subjects using Osteoboost displayed an 82% reduction in the rate of bone strength loss. Moreover, there was an 85% reduction in loss of bone density.
Laura Bilek, Ph.D., the principal investigator, highlighted the importance of novel technology in mitigating bone loss post-menopause. Additionally, Laura Yecies, CEO of Bone Health Technologies, emphasized the significance of a non-pharmacological intervention. Osteoboost, a wearable device, employs targeted vibration to the lumbar spine and hips.
The study paves the way for empowering postmenopausal women to maintain their bone health, keeping them active and independent.v